The OCT1-transfected cells also exhibited significantly more susceptible to the cytotoxicity of irinotecan and paclitaxel when compared with mock cells, suggesting that OCT1 may contribute to accumulation of the selected antineoplastic drugs in cancer cells. Here, SLC22A1 is linked to cancer.